Merck reported fourth quarter earnings and revenue that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products. The company posted adjusted earnings per share of $2.04, compared with analyst expectations of $2.01. Revenue reached $16.4 billion, up 5% from the same period a year ago and above the $16.19 billion […]

The postMerck (MRK) stock slides on patent expiration worriesappeared first onRolling Out.